⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
CADL News
Candel Therapeutics, Inc. Common Stock
Candel Therapeutics Reports Extended Survival Tail Observed in Trial of Aglatimagene Besadenovec (CAN-2409) in Advanced Non-Small Cell Lung Cancer Patients with Inadequate Response to Immune Checkpoint Inhibitors
globenewswire.com
CADL
Form 8-K
sec.gov
CADL
Candel Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Highlights
globenewswire.com
CADL
Candel Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Highlights
globenewswire.com
CADL
Candel Therapeutics To Present New Data after Extended Follow Up from Randomized Phase 3 Trial of Aglatimagene Besadenovec in Localized Prostate Cancer at the American Urological Association 2026 Annual Meeting
globenewswire.com
CADL
Candel Therapeutics To Present New Data after Extended Follow Up from Randomized Phase 3 Trial of Aglatimagene Besadenovec in Localized Prostate Cancer at the American Urological Association 2026 Annual Meeting
globenewswire.com
CADL
Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com
CADL
Candel Therapeutics to Present at TD Cowen’s 46th Annual Health Care Conference in Boston
globenewswire.com
CADL
Form 8-K
sec.gov
CADL
Candel Therapeutics Announces Pricing of Public Offering
globenewswire.com
CADL